AU2002232401A1 - Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease - Google Patents
Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's diseaseInfo
- Publication number
- AU2002232401A1 AU2002232401A1 AU2002232401A AU3240102A AU2002232401A1 AU 2002232401 A1 AU2002232401 A1 AU 2002232401A1 AU 2002232401 A AU2002232401 A AU 2002232401A AU 3240102 A AU3240102 A AU 3240102A AU 2002232401 A1 AU2002232401 A1 AU 2002232401A1
- Authority
- AU
- Australia
- Prior art keywords
- alzheimer
- stimulating
- disease
- compositions
- microglial activation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 230000006724 microglial activation Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000004936 stimulating effect Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24560800P | 2000-11-03 | 2000-11-03 | |
| US60/245,608 | 2000-11-03 | ||
| PCT/US2001/042909 WO2002036166A2 (en) | 2000-11-03 | 2001-11-05 | Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002232401A1 true AU2002232401A1 (en) | 2002-05-15 |
Family
ID=22927376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002232401A Abandoned AU2002232401A1 (en) | 2000-11-03 | 2001-11-05 | Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20020102259A1 (en) |
| EP (1) | EP1349575A2 (en) |
| AU (1) | AU2002232401A1 (en) |
| CA (1) | CA2428023A1 (en) |
| MX (1) | MXPA03003919A (en) |
| WO (1) | WO2002036166A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003284968A1 (en) * | 2002-10-25 | 2004-05-13 | University Of South Florida | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
| WO2010065776A2 (en) * | 2008-12-03 | 2010-06-10 | The Salk Institute For Biological Studies | Identification of neuroprotective agents using pro-inflammatory human glial cells |
| EP2950102A1 (en) | 2014-05-30 | 2015-12-02 | Biocross, S.L. | Method for the diagnosis of alzheimer s disease and mild cognitive impairment |
| EP3067699A1 (en) | 2015-03-11 | 2016-09-14 | Neuron Bio, S.A. | Method for diagnosing alzheimer's disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001259215A1 (en) * | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
-
2001
- 2001-11-05 CA CA002428023A patent/CA2428023A1/en not_active Abandoned
- 2001-11-05 EP EP01991921A patent/EP1349575A2/en not_active Withdrawn
- 2001-11-05 AU AU2002232401A patent/AU2002232401A1/en not_active Abandoned
- 2001-11-05 US US09/985,598 patent/US20020102259A1/en active Pending
- 2001-11-05 MX MXPA03003919A patent/MXPA03003919A/en unknown
- 2001-11-05 WO PCT/US2001/042909 patent/WO2002036166A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002036166A2 (en) | 2002-05-10 |
| EP1349575A2 (en) | 2003-10-08 |
| WO2002036166A3 (en) | 2003-01-30 |
| MXPA03003919A (en) | 2003-09-25 |
| CA2428023A1 (en) | 2002-05-10 |
| US20020102259A1 (en) | 2002-08-01 |
| WO2002036166A8 (en) | 2003-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002219824A1 (en) | Compositions and methods for diagnosing alzheimer's disease | |
| AU2002328343A1 (en) | Wax-based compositions and the use thereof as body care agents | |
| AU2001233299A1 (en) | Methods for treating alzheimer's disease | |
| AU2001273132A1 (en) | Compounds to treat alzheimer's disease | |
| AU2001252135A1 (en) | Therapeutic agents | |
| AU2001278084A1 (en) | Model for alzheimer's disease and other neurodegenerative diseases | |
| HUP0302486A3 (en) | Antimicrobial and deodorant compositions and process for preparing the same | |
| AU3113500A (en) | Compositions for treating alzheimer's disease and other amyloidoses | |
| AU2002335794A1 (en) | Allylamides useful in the treatment of alzheimer's disease | |
| AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
| ZA200210278B (en) | 3-azabicyclo(3.1.0)hexane derivatives useful in therapy. | |
| AU2001290239A1 (en) | Medicinal composition | |
| AU2002212471A1 (en) | Peptides for use in the treatment of alzheimer's disease | |
| AU5647601A (en) | Hair treatment compositions | |
| AU2001274877A1 (en) | Pest treatment composition | |
| AU2001273972A1 (en) | Hair treatment composition | |
| AU2001232866A1 (en) | Skin care compositions | |
| AU2001248760A1 (en) | Preventives/remedies for alzheimer's disease | |
| GB0009609D0 (en) | Therapeutic compositions | |
| AU2002232401A1 (en) | Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease | |
| AU4426801A (en) | Composition based on sphingolipid and beta-hydroxy-acid for skin care | |
| AU2002215187A1 (en) | S-adenosylmethionine and derivatives thereof for the treatment and prevention ofalzheimer's disease | |
| AU2002222557A1 (en) | Interferon therapeutic effect-potentiating agents | |
| AU2002218494A1 (en) | Medicinal compositions and process for producing the same | |
| AU2001275696A1 (en) | Therapeutic agent |